BridgeBio Pharma, Inc. (BBIO) › Operating IncomeBridgeBio Pharma, Inc. (BBIO) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2017: -$43.86M2018: -$183.66M2019: -$266.24M2020: -$474.48M2021: -$576.63M2022: -$512.20M2023: -$607.37M2024: -$592.97M2025: -$523.41M-$523.41M2017Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$523.41M+11.7%2024-$592.97M+2.4%2023-$607.37M-18.6%2022-$512.20M+11.2%2021-$576.63M-21.5%2020-$474.48M-78.2%2019-$266.24M-45.0%2018-$183.66M-318.8%2017-$43.86M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share